Consistent with this concept, pharmacologically targeting cholesteryl ester synthesis by blocking acyl-Coenzyme A: cholesterol acyltransferase 1 (ACAT1) activity impaired androgen-independent, androgen receptor (AR)-negative PC3 prostate cancer cell growth [17]. The gene discussed is ACAT1; the disease is prostate cancer.